Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thalidomide + tegafur-uracil
- Development stage
- Unknown
- Lead developer
- Chang Gung Memorial Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
thalidomide + tegafur-uracil is an investigational combination therapy being evaluated as an adjuvant treatment to prevent the recurrence of hepatocellular carcinoma (HCC) in high-risk patients following surgical resection (hepatectomy). This regimen combines thalidomide, an immunomodulatory and antiangiogenic agent, with tegafur-uracil (UFT), an oral fluoropyrimidine chemotherapy. Thalidomide exerts its effects by inhibiting angiogenesis through the suppression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and by modulating the immune system via tumor necrosis factor-alpha (TNF-alpha) inhibition. Tegafur-uracil consists of tegafur, a prodrug of 5-fluorouracil (5-FU) that inhibits thymidylate synthase to disrupt DNA synthesis, and uracil, which competitively inhibits dihydropyrimidine dehydrogenase (DPD) to increase the bioavailability of 5-FU. This specific combination has been studied in Phase II clinical trials sponsored by Chang Gung Memorial Hospital.
- Brand names
- UFURThalomid
- Other names
- thalidomine-Chang Gung Memorial Hospital-hepatocellular carcinomathalidomide + UFTThalidomide and Tegafur-uracil
02
Targets
DPYD (Dihydropyrimidine dehydrogenase)CRBN (Cereblon)TS (Thymidylate synthase)
Beyond the preview
Go deeper on thalidomide + tegafur-uracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thalidomide + tegafur-uracil.